JAZZ short interest surges, indicating growing pessimism among investors

Daniel Torres

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Jazz Pharmaceuticals plc shares valued at $3,259,538 were sold by COZADD BRUCE C on Nov 18 ’25. At $181.09 per share, COZADD BRUCE C sold 18,000 shares. The insider’s holdings dropped to 390,826 shares worth approximately $68.68 million following the completion of this transaction.

Also, Carr Patricia sold 5,319 shares, netting a total of over 968,402 in proceeds. Following the sale of shares at $182.06 each, the insider now holds 7,012 shares.

Before that, Winningham Rick E had sold 5,500 shares from its account. In a trade valued at $994,728, the Director traded Jazz Pharmaceuticals plc shares for $180.86 each. Upon closing the transaction, the insider’s holdings decreased to 5,500 shares, worth approximately $1.56 million.

As published in their initiating research note from Deutsche Bank on July 15, 2025, Jazz Pharmaceuticals plc [JAZZ] has been a Buy and the price target has been revised to $152. Analysts at UBS upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early March. As of February 26, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for JAZZ. Earlier on February 13, 2025, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for JAZZ stock which previously was a “an Equal weight”.

Analyzing JAZZ Stock Performance

On last trading session, Jazz Pharmaceuticals plc [NASDAQ: JAZZ] plunged -0.19% to $175.74. The stock’s lowest price that day was $174.475, but it reached a high of $179.005 in the same session. During the last five days, there has been a surge of approximately 24.01%. Over the course of the year, Jazz Pharmaceuticals plc shares have jumped approximately 49.45%. Shares of the company reached a 52-week high of $182.99 on 11/18/25 and a 52-week low of $95.49 on 04/09/25.

Support And Resistance Levels for Jazz Pharmaceuticals plc (JAZZ)

According to the 24-hour chart, there is a support level at 173.81, which, if violated, would cause prices to drop to 171.88. In the upper region, resistance lies at 178.34. The next price resistance is at 180.94. RSI (Relative Strength Index) is 78.86 on the 14-day chart, showing overbought technical sentiment.

Is Jazz Pharmaceuticals plc subject to short interest?

Stocks of Jazz Pharmaceuticals plc saw a sharp rise in short interest on 2025-10-31 jumping by 0.39 million shares to 5.12 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 4.73 million shares. A jump of 7.56% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.76 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.76.

Which companies own the most shares of Jazz Pharmaceuticals plc (JAZZ)?

In terms of Jazz Pharmaceuticals plc share price expectations, FactSet research, analysts set an average price target of 194 in the next 12 months, up nearly 10.18% from the previous closing price of $176.08. Analysts anticipate Jazz Pharmaceuticals plc stock to reach 205 by 2025, with the lowest price target being 152. In spite of this, 6 analysts ranked Jazz Pharmaceuticals plc stock as Buy at the end of 2025. On December 12, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $175.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.